NCT06515613View on ClinicalTrials.gov

A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

July 10, 2024

Primary Completion Date

July 30, 2027

Study Completion Date

March 31, 2028

Conditions
Platinum-resistant Ovarian CancerTesticular CancerEndometrial Cancer
Interventions
DRUG

CTIM-76

Claudin 6 bispecific Antibody administered weekly (Day 1, 8, 15 and 22) of a 28 day treatment cycle until disease progression.

Trial Locations (8)

10021

RECRUITING

Context Investigational Site, New York

19111

RECRUITING

Context Investigational Site, Philadelphia

44718

RECRUITING

Context Investigational Site, Canton

72205

RECRUITING

Context Investigational Site, Little Rock

75230

RECRUITING

Context Investigational Site, Dallas

97213

RECRUITING

Context Investigational Site, Portland

07601

RECRUITING

Context Investigational Site, Hackensack

02905

RECRUITING

Context Investigational Site, Providence

Sponsors
All Listed Sponsors
lead

Context Therapeutics Inc.

INDUSTRY